Finance

Beta
Lists
HYL:EBR
Hyloris Pharmaceuticals SA
€4.92
-0.61%
(-0.030) 1D
Jun 10, 4:10:24 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for HYL...
Open
€5.00
High
€5.00
Low
€4.92
Mkt. cap
137.76M
Avg. vol.
3.95K
Volume
895.00
52-wk high
€8.40
52-wk low
€4.51
EPS
-€0.23
Shares outstanding
28.00M
No. of employees
55
Open
€5.00
High
€5.00
Low
€4.92
Mkt. cap
137.76M
Avg. vol.
3.95K
Volume
895.00
52-wk high
€8.40
52-wk low
€4.51
EPS
-€0.23
Shares outstanding
28.00M
No. of employees
55
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to HYL in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for HYL in the last 3 months.
Highest
Current €4.92
€14.30 (+190.65%)
Average
€14.30 (+190.65%)
Lowest
€14.30 (+190.65%)
News stories
From sources across the web
About Hyloris Pharmaceuticals SA
CEOStijn Van Rompay
Employees55
Founded2012
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.67M
1.67M
2.30M
2.30M
Cost of goods sold
64.00K
64.00K
125.50K
125.50K
Cost of revenue
64.00K
64.00K
125.50K
125.50K
Research and development expenses
2.49M
2.49M
3.15M
3.15M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.10M
1.10M
1.34M
1.34M
Operating expense
3.37M
3.37M
4.49M
4.49M
Total operating expenses
3.43M
3.43M
4.61M
4.61M
Operating income
-1.76M
-1.76M
-2.31M
-2.31M
Other non operating income
500.00
500.00
87.00K
87.00K
EBT including unusual items
-1.86M
-1.86M
-1.50M
-1.50M
EBT excluding unusual items
-1.86M
-1.86M
-2.20M
-2.20M
Income tax expense
-81.00K
-81.00K
-106.00K
-106.00K
Effective tax rate
4.36%
4.36%
7.09%
7.09%
Other operating expenses
-222.00K
-222.00K
-6.50K
-6.50K
Net income
-1.78M
-1.78M
-1.39M
-1.39M
Net profit margin
-106.47%
-106.47%
-60.41%
-60.41%
Earnings per share
-
-
-
-
Interest and investment income
213.00K
213.00K
271.00K
271.00K
Interest expense
-304.50K
-304.50K
-14.00K
-14.00K
Net interest expenses
-91.50K
-91.50K
257.00K
257.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.61M
-1.61M
-2.00M
-2.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more